{"organizations": [], "uuid": "79fd6f4447da0d8ae205964309c8aa3f82195301", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180118.html", "section_title": "Archive News &amp; Video for Thursday, 18 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-pci-biotech-holding-extends-precli/brief-pci-biotech-holding-extends-preclinical-research-collaboration-idUSFWN1PD06A", "country": "US", "domain_rank": 408, "title": "BRIEF-PCI Biotech Holding Extends Preclinical Research Collaboration", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.005, "site_type": "news", "published": "2018-01-18T15:08:00.000+02:00", "replies_count": 0, "uuid": "79fd6f4447da0d8ae205964309c8aa3f82195301"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-pci-biotech-holding-extends-precli/brief-pci-biotech-holding-extends-preclinical-research-collaboration-idUSFWN1PD06A", "ord_in_thread": 0, "title": "BRIEF-PCI Biotech Holding Extends Preclinical Research Collaboration", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "brief-pci biotech holding extends preclinical research collaboration", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 18 (Reuters) - PCI BIOTECH HOLDING ASA:\n* EXTENDING PRECLINICAL RESEARCH COLLABORATION WITH UNDISCLOSED TOP-10 PHARMA COMPANY, INITIATED IN SEPTEMBER 2015â€‹\n* WILL EVALUATE DATA GENERATED AND EXPLORE POTENTIAL FOR FURTHER PARTNERSHIP BASED ON OUTCOME\n* - EXTENDED EVALUATION PERIOD SPANS OVER 6 MONTHS, UNTIL THE END OF JUNE 2018, AND MAY BE FURTHER EXTENDED Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-18T15:08:00.000+02:00", "crawled": "2018-01-19T12:31:25.001+02:00", "highlightTitle": ""}